
SUPPLEMENTARY FIGURE



Supplementary Figure 1. NBP alleviated the abnormal accumulation of glucose and citric acid, improved the levels of metabolites involved in the glutamate-glutamine cycle. (A), enhanced ATP metabolism (B), and increased the levels of antioxidants (C) in a rat model of pMCAO. MALDI-TOF-MS imaging of glucose ($215 \pm 0.2 \text{ Da}$), citric acid ($191.05 \pm 0.1 \text{ Da}$), glutamate ($146.07 \pm 0.1 \text{ Da}$), glutamine ($145.07 \pm 0.1 \text{ Da}$), ATP ($505.85 \pm 0.1 \text{ Da}$), ADP ($425.97 \pm 0.1 \text{ Da}$), AMP ($346.01 \pm 0.1 \text{ Da}$), GMP ($362.01 \pm 0.1 \text{ Da}$), taurine ($124.05 \pm 0.1 \text{ Da}$), glutathione ($306.05 \pm 0.1 \text{ Da}$), and ascorbic acid ($175.05 \pm 0.1 \text{ Da}$). The spatial resolution was set to $100 \,\mu$ m. Scale bar = 5 mm. Sham: sham surgery group; pMCAO: permanent middle cerebral artery occlusion group; NBP: dl-3-n-butylphthalide-treated group.